Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (206)
  2. Journal Article (120)
  3. Review (18)
  4. Research Letter (7)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (1)
Groups
  1. Adult Leukemia (359)
  2. Center for Hematologic Malignancies (359)
  3. Department of Medicine (359)
  4. Hematologic Malignancies, Division of (359)
  5. GSK Faculty (183)
  6. Hematologic Malignancies Research (140)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (83)
  3. Michel Sadelain (81)
  4. Martin Tallman (79)
  5. Maria Palomba (73)
  6. Xiuyan Wang (65)

More People

Years
  1. 2025 (20)
  2. 2024 (25)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (134)
  2. Journal of Clinical Oncology (30)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (148)
  2. Elsevier Inc. (34)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (29)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (359)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia patients at first relapse: A multi-center outcomes analysis
    Meeting Abstract

    Hu, R.; Wei, W.; Gonter-Aubin, K.; Pinilla Ibarz, J.; Kabel, C. C.; Mato, A. R.; Madanat, Y. F.; Khajavian, S.; Shadman, M.; Hanlon, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Management of CAR T-cell toxicities: Concordance and divergence between healthcare providers and expert consensus recommendations
    Meeting Abstract

    Frigault, M.; Cartwright, M.; Marcello, K.; Quill, T. A.; DeAngelo, D. J.; Galinsky, I.; Paul, S.; Park, J. H.
    Blood (2019)

    Fulltext@MSK | Save
  • Pegaspargase can safely be administered in adults age 40 and older with acute lymphoblastic leukemia
    Meeting Abstract

    Daley, R. J.; Rajeeve, S.; Kabel, C. C.; Pappacena, J. J.; Stump, S. E.; Lavery, J. A.; Tallman, M. S.; Geyer, M. B.; Park, J. H.
    Blood (2019)

    Fulltext@MSK | Save
  • Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy
    Meeting Abstract

    Smith, M.; Littmann, E.; Slingerland, J.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Peled, J. U.; Park, J.; O'Cearbhaill, R.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements
    Meeting Abstract

    Faramand, R.; Kotani, H.; Morrissey, D.; Yu, B.; Locke, F. L.; Jain, M.; Chavez, J. C.; Wang, X.; Mishra, A.; Bachmeier, C. A.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Chimeric antigen receptor-T cells for leukemias in adults: Methods, data and challenges
    Book Section

    Geyer, M. B.; Park, J. H.; Brentjens, R. J.
    In Perales, M. A.; Abutalib, S. A.; Bollard, C. (Eds.) Cell and Gene Therapies (2019)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
    Journal Article

    Saygin, C.; Kishtagari, A.; Cassaday, R. D.; Reizine, N.; Yurkiewicz, I.; Liedtke, M.; Stock, W.; Larson, R. A.; Levine, R. L.; Tallman, M. S.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Management of recurrent acute lymphoblastic leukemia with T-cell engagement: CAR T, BiTEs, and beyond
    Review

    Park, J.
    Journal of the National Comprehensive Cancer Network (2019)

    Fulltext@MSK | Save